Explore more publications!

The Middle East Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Gazette.

Press releases published on March 16, 2026

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
K2 Corporate Mobility’s growth leads the company to rebrand 
Pan American Energy Commences Drilling at the Tharsis Project
Maxus Mining Confirms Strong Polymetallic Results at the Quarry Antimony Property in British Columbia, Canada
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
DPM Metals Announces Renewal of Normal Course Issuer Bid
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
Enlight Secures $304 Million in Project Financing for the Crimson Orchard Project in Idaho, USA
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GFM Announces Non-Brokered Private Placement
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Tower Semiconductor Teams up with Oriole to Advance AI Infrastructure and Networking with Nanosecond Optical Circuit Switching
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Allot to Participate in the 38th Annual Roth Conference on March 23-24, 2026
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions